| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $543,301 ) |
| | 2024 | 2024 | HDT BIO CORP | 1150 EASTLAKE AVE E STE 200A | SEATTLE | WA | 98109-4413 | KING | USA | R61AI169207 | RNA Vaccine Innovations for TB: Targeting the Mucosa | 000 | 3 | NIH | 4/4/2024 | $271,651 |
| | 2024 | 2024 | HDT BIO CORP | 1150 EASTLAKE AVE E STE 200A | SEATTLE | WA | 98109-4413 | KING | USA | R61AI169207 | RNA Vaccine Innovations for TB: Targeting the Mucosa | 000 | 3 | NIH | 4/4/2024 | $271,650 |
| | 2024 | 2021 | HDT BIO CORP | 1150 EASTLAKE AVE E STE 200A | SEATTLE | WA | 98109-4413 | KING | USA | R43CA265564 | Targeting and Imaging Ovarian Cancer with Junction Opener Conjugated-Lipid Iron Oxide Nanoparticles (JOC-LIONs) | 000 | 1 | NIH | 2/13/2024 | $0 |
| | 2024 | 2021 | HDT BIO CORP | 1150 EASTLAKE AVE E STE 200A | SEATTLE | WA | 98109-4413 | KING | USA | R43AI165100 | Development of an adaptable RNA vaccine against enterovirus D68 infection for the prevention of acute flaccid myelitis | 000 | 1 | NIH | 11/6/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $2,011,163 ) |
| | 2023 | 2023 | HDT BIO CORP. | 1616 Eastlake Ave E Ste 280 | Seattle | WA | 98102-3788 | KING | USA | R43IP001229 | PA21259, SBIR Phase I, Developing a RIG-I agonist to prevent COVID-19 | 00 | 1 | CDC | 8/30/2023 | $299,984 |
| | 2023 | 2023 | HDT BIO CORP. | 1616 EASTLAKE AVE E STE 280 | SEATTLE | WA | 98102-3788 | KING | USA | R43AI177181 | Development of a RIG-I agonist RNA as a cure for chronic Hepatitis B | 000 | 1 | NIH | 4/14/2023 | $275,211 |
| | 2023 | 2023 | HDT BIO CORP. | 1616 EASTLAKE AVE E STE 280 | SEATTLE | WA | 98102-3788 | KING | USA | R43AI170395 | Development of a single-dose self-amplifying RNA vaccine for boosting pre-existing influenza virus immunity, driving B and T cell responses to conserved targets | 000 | 2 | NIH | 4/28/2023 | $192,720 |
| | 2023 | 2023 | HDT BIO CORP. | 1616 EASTLAKE AVE E STE 280 | SEATTLE | WA | 98102-3788 | KING | USA | R61AI161811 | Engineering the Immune Response of a Self-replicating and Adjuvanting RNA HIV-1Vaccine | 000 | 3 | NIH | 3/23/2023 | $940,253 |
| | 2023 | 2023 | HDT BIO CORP. | 1616 EASTLAKE AVE E STE 280 | SEATTLE | WA | 98102-3788 | KING | USA | R61AI169207 | RNA Vaccine Innovations for TB: Targeting the Mucosa | 000 | 2 | NIH | 3/21/2023 | $269,037 |
| | 2023 | 2023 | HDT BIO CORP. | 1616 EASTLAKE AVE E STE 280 | SEATTLE | WA | 98102-3788 | KING | USA | R61AI169207 | RNA Vaccine Innovations for TB: Targeting the Mucosa | 000 | 2 | NIH | 3/21/2023 | $269,037 |
| | 2023 | 2021 | HDT BIO CORP. | 1616 EASTLAKE AVE E STE 280 | SEATTLE | WA | 98102-3788 | KING | USA | R21AI144641 | Assessing immunogenicity of LepVax: a new leprosy vaccine in clinical development | 000 | 2 | NIH | 7/19/2023 | -$221,223 |
| | 2023 | 2021 | HDT BIO CORP. | 1616 EASTLAKE AVE E STE 280 | SEATTLE | WA | 98102-3788 | KING | USA | R43AI162278 | Development of CoroDetecT, a skin test for SARS-CoV-2 infection | 000 | 1 | NIH | 5/3/2023 | -$13,856 |
| | 2023 | 2021 | HDT BIO CORP. | 1616 EASTLAKE AVE E STE 280 | SEATTLE | WA | 98102-3788 | KING | USA | R43AI162278 | Development of CoroDetecT, a skin test for SARS-CoV-2 infection | 002 | 1 | NIH | 6/16/2023 | $13,856 |
| | 2023 | 2021 | HDT BIO CORP. | 1616 EASTLAKE AVE E STE 280 | SEATTLE | WA | 98102-3788 | KING | USA | R43AI162278 | Development of CoroDetecT, a skin test for SARS-CoV-2 infection | 001 | 1 | NIH | 5/15/2023 | -$13,856 |
|
| Issue Date FY: 2022 ( Subtotal = $1,701,885 ) |
| | 2022 | 2022 | HDT BIO CORP. | 1616 EASTLAKE AVE E STE 280 | SEATTLE | WA | 98102-3788 | KING | USA | R61AI169207 | RNA Vaccine Innovations for TB: Targeting the Mucosa | 000 | 1 | NIH | 4/22/2022 | $275,359 |
| | 2022 | 2022 | HDT BIO CORP. | 1616 EASTLAKE AVE E STE 280 | SEATTLE | WA | 98102-3788 | KING | USA | R61AI161811 | Engineering the Immune Response of a Self-replicating and Adjuvanting RNA HIV-1Vaccine | 000 | 2 | NIH | 3/15/2022 | $1,046,474 |
| | 2022 | 2022 | HDT BIO CORP. | 1616 EASTLAKE AVE E STE 280 | SEATTLE | WA | 98102-3788 | KING | USA | R43AI170395 | Development of a single-dose self-amplifying RNA vaccine for boosting pre-existing influenza virus immunity, driving B and T cell responses to conserved targets | 000 | 1 | NIH | 5/10/2022 | $104,692 |
| | 2022 | 2022 | HDT BIO CORP. | 1616 EASTLAKE AVE E STE 280 | SEATTLE | WA | 98102-3788 | KING | USA | R61AI169207 | RNA Vaccine Innovations for TB: Targeting the Mucosa | 000 | 1 | NIH | 4/22/2022 | $275,360 |
|
| Issue Date FY: 2021 ( Subtotal = $2,161,658 ) |
| | 2021 | 2021 | HDT BIO CORP. | 1616 EASTLAKE AVE E STE 280 | SEATTLE | WA | 98102-3788 | KING | USA | R61AI161811 | Engineering the Immune Response of a Self-replicating and Adjuvanting RNA HIV-1Vaccine | 000 | 1 | NIH | 4/9/2021 | $927,069 |
| | 2021 | 2021 | HDT BIO CORP. | 1616 EASTLAKE AVE E STE 280 | SEATTLE | WA | 98102-3788 | KING | USA | R21AI144641 | Assessing immunogenicity of LepVax: a new leprosy vaccine in clinical development | 001 | 2 | NIH | 4/26/2021 | $265,468 |
| | 2021 | 2021 | HDT BIO CORP. | 1616 EASTLAKE AVE E STE 280 | SEATTLE | WA | 98102-3788 | KING | USA | R43AI165100 | Development of an adaptable RNA vaccine against enterovirus D68 infection for the prevention of acute flaccid myelitis | 000 | 1 | NIH | 9/2/2021 | $299,976 |
| | 2021 | 2021 | HDT BIO CORP. | 1616 EASTLAKE AVE E STE 280 | SEATTLE | WA | 98102-3788 | KING | USA | R43AI162278 | Development of CoroDetecT, a skin test for SARS-CoV-2 infection | 000 | 1 | NIH | 3/16/2021 | $223,637 |
| | 2021 | 2021 | HDT BIO CORP. | 1616 EASTLAKE AVE E STE 280 | SEATTLE | WA | 98102-3788 | KING | USA | R43CA265564 | Targeting and Imaging Ovarian Cancer with Junction Opener Conjugated-Lipid Iron Oxide Nanoparticles (JOC-LIONs) | 000 | 1 | NIH | 8/27/2021 | $399,285 |
| | 2021 | 2020 | HDT BIO CORP. | 1616 EASTLAKE AVE E STE 280 | SEATTLE | WA | 98102-3788 | KING | USA | R21AI144641 | Assessing immunogenicity of LepVax: a new leprosy vaccine in clinical development | 000 | 1 | NIH | 2/9/2021 | $46,223 |
|
| Issue Date FY: 2020 ( Subtotal = $148,321 ) |
| | 2020 | 2020 | HDT BIO CORP. | 1616 EASTLAKE AVE E STE 400 | SEATTLE | WA | 98102-3797 | KING | USA | R21AI144641 | Assessing immunogenicity of LepVax: a new leprosy vaccine in clinical development | 000 | 1 | NIH | 5/21/2020 | $175,000 |
| | 2020 | 2018 | Hdt Bio Corp. | 1616 Eastlake Ave E Ste 400 | Seattle | WA | 98102-3797 | KING | USA | R43IP001109 | Engineering Nanoparticle Alum Adjuvants for Pandemic Influenza Vaccines | 03 | 1 | CDC | 2/26/2020 | -$26,679 |
|
| Issue Date FY: 2019 ( Subtotal = $0 ) |
| | 2019 | 2018 | Hdt Bio Corp. | 1616 Eastlake Ave E Ste 400 | Seattle | WA | 98102-3797 | KING | USA | R43IP001109 | Engineering Nanoparticle Alum Adjuvants for Pandemic Influenza Vaccines | 01 | 1 | CDC | 4/11/2019 | $0 |
| | 2019 | 2018 | Hdt Bio Corp. | 1616 Eastlake Ave E Ste 400 | Seattle | WA | 98102-3797 | KING | USA | R43IP001109 | Engineering Nanoparticle Alum Adjuvants for Pandemic Influenza Vaccines | 02 | 1 | CDC | 5/1/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $224,984 ) |
| | 2018 | 2018 | Hdt Bio Corp. | 1616 Eastlake Ave E Ste 400 | Seattle | WA | 98102-3797 | KING | USA | R43IP001109 | Engineering Nanoparticle Alum Adjuvants for Pandemic Influenza Vaccines | 00 | 1 | CDC | 8/30/2018 | $224,984 |
|
|
